Ribaxamase is a Recombinant Enzyme owned by Theriva Biologics, and is involved in 7 clinical trials, of which 6 were completed, and 1 is ongoing.
SYN-004 elicits antibacterial effect by targeting beta-lactam antibiotics. It reduces the antibiotic concentration in the intestine, to prevent adverse effects on the normal enteric flora. The lactamase enzyme breaks beta lactamase ring and deactivates the antibacterial properties of excess beta-lactam antibiotics. Thereby preserving the antibiotic mediated disruption of the gut flora which is responsible for the colonization of clostridium which can further prevent opportunistic C. difficile infection.
The revenue for Ribaxamase is expected to reach a total of $634m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ribaxamase NPV Report.
SYN-004 is under development for the protection of the gut microbiome from beta-lactam antibiotics used for the prevention of C. difficile infections, acute graft versus host disease (aGVHD) in allogeneic hematopoietic cell transplant and antibiotic-associated diarrhea (AAD). The drug candidate is administered orally. SYN-004 has structural and functional similarities to naturally occurring beta-lactamases in the gastrointestinal (GI) microflora. It has CDI and VRE colonization in allogeneic HCT recipients.
Theriva Biologics Overview
Theriva Biologics (Theriva), formerly Synthetic Biologics Inc, is a Biotechnology company. It develops novel therapeutics to treat gut microbiome. The company’s pipeline products include SYN-004 and SYN-010. Its SYN-010 is a proprietary, modified-release formulation which is intended to treat rritable bowel syndrome with constipation. Theriva’s SYN-004 is an oral prophylactic therapy for prevention of clostridium difficile infection, pathogenic overgrowth and the emergence of antimicrobial resistance. It develops preclinical monoclonal antibody therapies for the treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria. The company undertakes various research activities to develop therapeutics. It collaborates with various academic and pharmaceutical companies to develop its product candidates. Theriva is headquartered in Rockville, Maryland, the US.
The operating loss of the company was US$14.3 million in FY2021, compared to an operating loss of US$10.2 million in FY2020. The net loss of the company was US$14.3 million in FY2021, compared to a net loss of US$10 million in FY2020.
Quick View – Ribaxamase
|Highest Development Stage|